• Author: Matsumoto, Shingo

    National Cancer Institute, United States

  • Author: Saito, Keita

    National Cancer Institute, United States

  • Author: Yasui, Hironobu

    National Cancer Institute, United States

  • Author: Morris, H. Douglas

    Mouse Imaging Facility, National Institute of Neurological Disorders and Stroke, United States

  • Author: Munasinghe, Jeeva P.

    Mouse Imaging Facility, National Institute of Neurological Disorders and Stroke, United States

  • Author: Lizak, Martin

    Mouse Imaging Facility, National Institute of Neurological Disorders and Stroke, United States

  • Author: Merkle, Hellmut

    Mouse Imaging Facility, National Institute of Neurological Disorders and Stroke, United States

  • Author: Ardenkjær-Larsen, Jan Henrik

    Biomedical Engineering, Department of Electrical Engineering, Technical University of Denmark, Elektrovej, 2800, Kgs. Lyngby, Denmark

  • Author: Choudhuri, Rajani

    National Cancer Institute, United States

  • Author: Devasahayam, Nallathamby

    National Cancer Institute, United States

  • Author: Subramanian, Sankaran

    National Cancer Institute, United States

  • Author: Koretsky, Alan P.

    Mouse Imaging Facility, National Institute of Neurological Disorders and Stroke, United States

  • Author: Mitchell, James B.

    National Cancer Institute, United States

  • Author: Krishna, Murali C.

    National Cancer Institute, United States

View graph of relations

The hypoxic nature of tumors results in treatment resistance and poor prognosis. To spare limited oxygen for more crucial pathways, hypoxic cancerous cells suppress mitochondrial oxidative phosphorylation and promote glycolysis for energy production. Thereby, inhibition of glycolysis has the potential to overcome treatment resistance of hypoxic tumors. Here, EPR imaging was used to evaluate oxygen dependent efficacy on hypoxia-sensitive drug. The small molecule 3-bromopyruvate blocks glycolysis pathway by inhibiting hypoxia inducible enzymes and enhanced cytotoxicity of 3-bromopyruvate under hypoxic conditions has been reported in vitro. However, the efficacy of 3-bromopyruvate was substantially attenuated in hypoxic tumor regions (pO(2) < 10 mmHg) in vivo using squamous cell carcinoma (SCCVII)-bearing mouse model. Metabolic MRI studies using hyperpolarized (13) C-labeled pyruvate showed that monocarboxylate transporter-1 is the major transporter for pyruvate and the analog 3-bromopyruvate in SCCVII tumor. The discrepant results between in vitro and in vivo data were attributed to biphasic oxygen dependent expression of monocarboxylate transporter-1 in vivo. Expression of monocarboxylate transporter-1 was enhanced in moderately hypoxic (8-15 mmHg) tumor regions but down regulated in severely hypoxic (<5 mmHg) tumor regions. These results emphasize the importance of noninvasive imaging biomarkers to confirm the action of hypoxia-activated drugs.
Original languageEnglish
JournalMagnetic Resonance in Medicine
Volume69
Issue number5
Pages (from-to)1443-1450
ISSN0740-3194
DOIs
StatePublished - 2013
Peer-reviewedYes
CitationsWeb of Science® Times Cited: 13

Keywords

  • Bromopyruvate, Hypoxic, Tumor, Pyruvate, Glycolysy, EPR imaging, Monocarboxylate, Monocarboxylate transporter, Transporter, Oxygen, mry, Hyperpolarized 13C MRI, Biomarker, Pyruvate metabolism , mmhg
Download as:
Download as PDF
Select render style:
APAAuthorCBE/CSEHarvardMLAStandardVancouverShortLong
PDF
Download as HTML
Select render style:
APAAuthorCBE/CSEHarvardMLAStandardVancouverShortLong
HTML
Download as Word
Select render style:
APAAuthorCBE/CSEHarvardMLAStandardVancouverShortLong
Word

ID: 12684386